# Brown Biotech Daily Tech Digest — 2026-06-02 > 매일 아침 AI·바이오텍·펩타이드 시장 시그널을 수집하고, > Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. ## 🔬 Today's Top Signals ### 1. [Isomorphic Labs announces Series B investment round](https://www.isomorphiclabs.com/articles/isomorphic-labs-announces-series-b-investment-round) $2.1B+ raise confirms AI-drug-design is a Big Tech priority. Directly validates the AI-pharma partnership model Isomorphic is building with J&J. Signals more Big Tech capital流入 AI-biotech. Brown should watch for CDMO/peptide outsourcing demand from AI-designed pipeline. ### 2. [Lilly's $1.2B deal for Hanmi GLP-2 drug for short bowel syndrome](https://www.fiercebiotech.com/biotech/lilly-pens-12b-deal-hanmis-glp-2-drug-being-aimed-short-bowel-syndrome) Jun 1, 2026. Peptide GLP-2 deal underscores sustained big-pharma appetite for peptide assets. Lilly continues its peptide shopping spree. Watch for Brown peptide-service capacity being tapped indirectly through partner networks. ### 3. [FDA Issues Draft Guidance to Cut Unnecessary Animal Testing for Cancer Drugs](https://www.fda.gov/news-events/press-announcements/fda-issues-draft-guidance-cut-unnecessary-animal-testing-cancer-drugs) May 29, 2026. Regulatory shift: FDA moving toward in silico / AI-driven safety assessment. Reduces preclinical barrier for novel peptide/ biologic candidates. Supports Brown position in AI-enabled drug design. ### 4. [ASCO, Ryght AI team up for breast cancer trial site selection](https://www.fiercebiotech.com/cro/asco-ryght-ai-team-breast-cancer-trial-site-selection) Jun 1, 2026. AI entering clinical trial operations — site selection is a workflow ripe for agentic automation. If Ryght AI scales this model, AI-driven trial infrastructure becomes a new ops category Brown should track. ### 5. [Agios signs $165M deal for blood disorder drug that failed study](https://www.fiercebiotech.com/biotech/agios-agrees-165m-blood-disorder-drug-koreas-oscotec-flunked-phase-2-study) Jun 1, 2026. Interesting licensing pattern: Phase 2 failure didn't kill the asset. Shows买家 are doing due diligence on late-stage attrition risk. Could be a model for Brown proof-of-concept strategy — failure is not final if the right partner sees residual value. ## 💡 Brown Biotech Insights - **peptide-service:** GLP-2 / GLP-1 pipeline activity remains hot. Lilly-Hanmi deal signals continued big-pharma appetite for validated peptide targets. Brown should maintain CDMO capacity awareness and potential inbound from this deal flow. - **biostatx / genox-site:** FDA draft guidance on reducing animal testing is a directional signal for in silico PK/tox modeling. Short-term: watch for partner interest in AI-augmented preclinical packages. - **business-pipeline:** Isomorphic's $2.1B raise and J&J collaboration validates AI-first drug design model. Brown should frame its AI-ops integration story in the same language — faster cycle, proof-of-function, not just cost play. - **AI agent / coding utility:** Stanford CS336 AI Agent Guidelines and the ASCO-Ryght partnership both point to agentic AI embedding in scientific workflows. Brown should consider what "AI-native ops" looks like for its own service delivery. ### Next Action (ONE concrete step only) - Draft a one-pager on "What Isomorphic's $2.1B raise means for AI-biotech CDMO demand" and share with peptide-service team to assess capacity positioning. ## 🎯 Next Action - Draft a one-pager on "What Isomorphic's $2.1B raise means for AI-biotech CDMO demand" and share with peptide-service team to assess capacity positioning. --- _Published 2026-06-08 13:03 KST · [brownbio.tech](https://brownbio.tech) · Source: Hacker News, GeekNews, Reddit ML/bioinformatics, Science Immunology_
2026-06-02